Navigation Links
Ambry Genetics Announces Illumina CSPro Certification for GA Sequencing
Date:4/28/2009

ALISO VIEJO, Calif., April 28 /PRNewswire/ -- Ambry Genetics announced today that it has successfully completed Illumina CSPro(TM) certification for Genome Analyzer (GA) Sequencing, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.

Anja Kammesheidt, PhD, Ambry's CSO, said, "that the company has been working on the Illumina GA systems since January 2008. We are offering standard GA Sequencing services to pharma, clinical and academic research groups, while keeping up with Illumina's technology improvements. We value Illumina's commitment to innovation and quality, and are excited to now be the second CSPro in the USA for the GA applications."

"Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Director of Corporate Marketing. "Ambry Genetics is the now a Certified Service Provider able to offer Illumina Genome Analyzer Sequencing services using Illumina technology. Now that Ambry Genetics is a global CSPro partner, we are excited to work with them to make it easier for researchers to access the power of Illumina's genetic analysis technologies."

About Ambry Genetics

Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics, pharmacogenomics and research support. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies. To learn more about testing and services available through Ambry, visit www.ambrygen.com.

This report contains forward-looking statements about the Company's future plans, strategies, objectives, goals and expectations, including projections, estimates, prospects, returns and performance of the Company. Forward-looking statements can be identified by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "estimate," "intend," "continue," or "believe" or the negatives thereof or other variations thereof or comparable terminology. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. In light of the significant uncertainties inherent in the forward-looking statements made in this report the inclusion of such information should not be regarded as a representation or warranty, express or implied, by the Company or any other person that the objectives and plans of the Company will be achieved.


'/>"/>
SOURCE Ambry Genetics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genetics Hold Promise, Challenges for Cancer Care
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
4. Obesity genetics
5. The genetics of MLL leukemogenesis
6. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
9. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
10. Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
11. Response Genetics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... the perfect set of tools for video editors that want to create the illusion of ... CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic depth ... focus from one area into the next. ProDOF comes with 0.5 second, 1.0 second, ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The dermatology ... of cosmetic services. , “We’re excited to add this excellent dermatology practice to ...
(Date:1/20/2017)... ... ... New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is ... be wheeled out of the way and stored when not in use. It is freestanding ... feedback from customers into specific enhancements and created a new product that is built directly ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Doctor C LLC, ... attended the January ECRM trade show to continue the marketing and distribution of its ... supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. At ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin ... global anti-obesity drugs market is expected to grow at ... period and CAGR of 38.7% in the second half of the ... of 32.8% from 2016 to 2027. The market is estimated at ... in 2027. ...
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
Breaking Medicine Technology: